H102
Haloperidol metabolite II
analytical standard
Synonym(s):
(±)-4-(4-Chlorophenyl)-α-(4-fluorophenyl)-4-hydroxy-1-piperidinebutanol, Reduced Haloperidol
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C21H25ClFNO2
CAS Number:
Molecular Weight:
377.88
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
analytical standard
Quality Level
assay
≥98% (HPLC)
form
solid
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
color
white
solubility
DMSO: 10 mg/mL
application(s)
forensics and toxicology
pharmaceutical (small molecule)
veterinary
format
neat
SMILES string
OC(CCCN1CCC(O)(CC1)c2ccc(Cl)cc2)c3ccc(F)cc3
InChI
1S/C21H25ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,20,25-26H,1-2,11-15H2
InChI key
WNZBBTJFOIOEMP-UHFFFAOYSA-N
Application
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
J G Shin et al.
British journal of clinical pharmacology, 51(1), 45-52 (2001-02-13)
We evaluated the inhibitory effect of haloperidol and its metabolites on CYP2D6 activity in order to better understand the potential role of these metabolites in drug interactions involving haloperidol. The inhibitory effects of haloperidol and five of its metabolites on
J M Leroux et al.
Progress in neuro-psychopharmacology & biological psychiatry, 18(2), 347-353 (1994-03-01)
1. The authors attempted to correlate plasma concentrations in H/rH and clinical efficacy from 8 schizophrenic patients (DSM IIIR) on H. 2. No significant correlations were found between H, rH plasma levels and positive and negative subscale for each patient.
S Ulrich et al.
International clinical psychopharmacology, 14(4), 219-228 (1999-09-01)
The aim of this study was to investigate the effect of reduced haloperidol, the main metabolite of the antipsychotic drug haloperidol, on psychopathology improvement and extrapyramidal adverse effects in acute schizophrenia. The steady-state pharmacokinetics of reduced haloperidol was studied. Serum